X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 91 filers reported holding X4 PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $246,733 | -61.0% | 226,361 | -30.5% | 0.00% | -50.0% |
Q2 2023 | $632,289 | +2297.9% | 325,922 | +975.4% | 0.00% | – |
Q1 2023 | $26,368 | +31.6% | 30,308 | +50.2% | 0.00% | – |
Q4 2022 | $20,039 | -64.2% | 20,180 | -38.6% | 0.00% | – |
Q3 2022 | $56,000 | +86.7% | 32,876 | +94.0% | 0.00% | – |
Q1 2022 | $30,000 | -3.2% | 16,950 | +23.3% | 0.00% | – |
Q4 2021 | $31,000 | +181.8% | 13,750 | +560.1% | 0.00% | – |
Q3 2021 | $11,000 | – | 2,083 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |